离子通道应用报告
使用非放射性分析作为膜蛋白调节剂的筛选工具在科学文献中有很好的记载，并已被广泛用于研究钾通道家族。同样的非放射性Rb+分析原理可以很容易地应用于比目前验证的更多的膜蛋白靶点。以下出版物是ICR应用程序的部分集合，对制药实验室和学术机构都有用。请联系Aurora以获取有关您的特定实验要求的更多信息。
通量分析概述
离子通道筛选的非放射性铷流出分析技术
Nonradioactive Rubidium Efflux Assay Technology for Screening of Ion Channels
Georg C. Terstappen
了解更多
离子通道分析的离子通量和配体结合分析
Ion Flux and Ligand Binding Assays for Analysis of Ion Channels
Georg C. Terstappen
了解更多
技术报告
使用ICR8000验证心肌细胞的内源性Na，K，-ATPase的表达
Validation of endogenously expressed Na, K, -ATPase in Cor.At Cardiomyocytes using ICR8000
了解更多
针对特定研究目标的出版物
新兴应用
导电膜蛋白质在结构和功能上都是多样的。这种异质性是至关重要的服务范围广泛的生理作用。Aurora的ICR分析满足客户的需求，真诚地努力走在前沿，开拓解决具有挑战性问题的新途径。我们的科学家目前正在与制药和学术合作伙伴合作，开发新的和有效的基于ICR的分析方法，用于转运蛋白、天然化合物和癌症标志物的研究。
Electrogenic membrane proteins are diverse in both structure and function. This heterogeneity is vital to serving a wide array of physiological roles. At Aurora, we take pride in tailoring our ICR assay to fit our clients’ needs. We make a sincere effort to get out in front of the field and pioneer new means of tackling challenging problems. Our scientists are currently collaborating with pharmaceutical and academic partners to develop new and effective ICR-based assays for use in transporter, natural product, and cancer biomarker study.
Applications
Publications
- • Nonradioactive Rubidium Efflux Assay Technology for Screening of Ion Channels（Georg C. Terstappen）
- • Ion Flux and Ligand Binding Assays for Analysis of Ion Channels（Georg C. Terstappen）
- • Development and validation of HTS assay for screening the calcium-activated chloride channel modulators in TMEM16A stably expressed CHO cells
- • Screening technologies for ion channel drug discovery
- • Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K+ channel
- • High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5
- • Cellular HTS Assays for Pharmacological Characterization of Na V 1.7 Modulators
- • Zinc pyrithione-mediated activation of voltage-gated KCNQ potassium channels rescues epileptogenic mutants
- • Evaluation of the Rubidium Efflux Assay for Preclinical Identification of hERG Blockade
- • Characterization of a hERG Screen Using the IonWorks HT: Comparison to a hERG Rubidium Efflux Screen
- • Development of an HTS Assay for Na , K -ATPase Using Nonradioactive Rubidium Ion Uptake
- • Rb + Flux through hERG Channels Affects the Potency of Channel Blocking Drugs: Correlation with Data Obtained Using a High-Throughput Rb + Efflux Assay
- • Atomic Absorption Spectroscopy in Ion Channel Screening
- • Nonradioactive Rubidium Ion Efflux Assay and Its Applications in Drug Discovery and Development
- • Validation of an Atomic Absorption Rubidium Ion Efflux Assay for KCNQ/M-Channels Using the Ion Channel Reader 8000
- • High Throughput Assay Technologies for Ion Channel Drug Discovery
- • A High Throughput Screening Techno logy-Overcoming Bottlenecks in Ion Channel Drug Targets
- • A medium-throughput functional assay of KCNQ2 potassium channels using rubidium efflux and atomic absorption spectrometry